BioNTech SE - ADR vs United Airlines Holdings Inc — how do they compare? BioNTech SE - ADR trades at $90.14 (market cap $22.86B), while United Airlines Holdings Inc trades at $121.5 (market cap $39.06B). The key difference: United Airlines Holdings Inc is the larger of the two by market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | UAL | |
|---|---|---|
Market Cap | $22.86B | $39.06B |
Sector | Health | Industrials |
52-Week High | $119.34 | $136.11 |
52-Week Low | $83.89 | $84.57 |
Enterprise Value | $6.53B | $55.87B |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
United Airlines (UAL) trades at $121.16, down 3.84% amid sector volatility, with strong fundamentals including a P/E of 10.84 and net income margin of 6.06%. Recent earnings beats and a bullish analyst consensus (66% buy ratings) support a $160.88 price target. Cash flow trends show operational strength despite net outflows, while technical indicators signal near-term support at $120.
Outlook remains positive with projected revenue growth to $60.5B in 2026, though risks include fuel cost spikes and competitive pressures. The stock offers value with low valuation multiples and consistent earnings outperformance, positioning it for recovery if macroeconomic headwinds ease.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →